PT671905E - Composicoes estaveis de proteinas: fosfolipidos e respectivos metodos - Google Patents

Composicoes estaveis de proteinas: fosfolipidos e respectivos metodos

Info

Publication number
PT671905E
PT671905E PT94929959T PT94929959T PT671905E PT 671905 E PT671905 E PT 671905E PT 94929959 T PT94929959 T PT 94929959T PT 94929959 T PT94929959 T PT 94929959T PT 671905 E PT671905 E PT 671905E
Authority
PT
Portugal
Prior art keywords
protein
phospholipids
methods
protein compositions
stable protein
Prior art date
Application number
PT94929959T
Other languages
English (en)
Inventor
David Collins
Younsik Cha
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of PT671905E publication Critical patent/PT671905E/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/193Colony stimulating factors [CSF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Dispersion Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
PT94929959T 1993-10-06 1994-09-29 Composicoes estaveis de proteinas: fosfolipidos e respectivos metodos PT671905E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13241393A 1993-10-06 1993-10-06

Publications (1)

Publication Number Publication Date
PT671905E true PT671905E (pt) 2002-12-31

Family

ID=22453938

Family Applications (1)

Application Number Title Priority Date Filing Date
PT94929959T PT671905E (pt) 1993-10-06 1994-09-29 Composicoes estaveis de proteinas: fosfolipidos e respectivos metodos

Country Status (21)

Country Link
EP (1) EP0671905B1 (pt)
JP (1) JP2852127B2 (pt)
KR (1) KR100372006B1 (pt)
CN (1) CN1206982C (pt)
AT (1) ATE222752T1 (pt)
AU (1) AU683698B2 (pt)
CA (1) CA2150939C (pt)
CZ (1) CZ290029B6 (pt)
DE (1) DE69431236T2 (pt)
DK (1) DK0671905T3 (pt)
ES (1) ES2184768T3 (pt)
FI (1) FI116271B (pt)
HK (1) HK1010341A1 (pt)
HU (1) HUT72326A (pt)
IL (1) IL111170A (pt)
NO (1) NO314064B1 (pt)
NZ (1) NZ274705A (pt)
PT (1) PT671905E (pt)
RU (1) RU2119791C1 (pt)
WO (1) WO1995009611A2 (pt)
ZA (1) ZA947782B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874075A (en) * 1993-10-06 1999-02-23 Amgen Inc. Stable protein: phospholipid compositions and methods
US7863238B2 (en) 2004-06-10 2011-01-04 Saint Louis University Proteins with an attached short peptide of acidic amino acids
US7972593B2 (en) 2004-06-10 2011-07-05 Saint Louis University Delivery of therapeutic agents to the bone
JP2006248978A (ja) * 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
EP2259768B1 (en) 2008-04-08 2019-05-22 Merck Patent GmbH Compositions containing cyclic peptides and methods of use
CN104507953B (zh) * 2012-05-31 2018-05-18 新加坡科技研究局 通过用正电性有机添加剂处理来降低蛋白质制剂中蛋白质-污染物复合物和聚集物水平的方法
AU2015242791B2 (en) * 2014-04-04 2017-08-17 Osaka University Drug Delivery Enhancer Comprising Substance For Activating Lysophospholipid Receptors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4208527A1 (de) * 1992-03-17 1993-09-23 Max Planck Gesellschaft Liposomen mit negativer ueberschussladung
JPH06247842A (ja) * 1993-02-23 1994-09-06 Green Cross Corp:The リポソーム組成物の製造方法

Also Published As

Publication number Publication date
FI952738A (fi) 1995-07-31
NO952210L (no) 1995-08-04
DK0671905T3 (da) 2002-10-07
EP0671905B1 (en) 2002-08-28
NO952210D0 (no) 1995-06-02
CN1206982C (zh) 2005-06-22
FI116271B (fi) 2005-10-31
ATE222752T1 (de) 2002-09-15
ES2184768T3 (es) 2003-04-16
JP2852127B2 (ja) 1999-01-27
KR100372006B1 (ko) 2003-07-18
CZ143895A3 (en) 1996-01-17
RU2119791C1 (ru) 1998-10-10
CZ290029B6 (cs) 2002-05-15
IL111170A0 (en) 1994-12-29
HUT72326A (en) 1996-04-29
CA2150939A1 (en) 1995-04-13
CN1117266A (zh) 1996-02-21
NZ274705A (en) 1997-12-19
WO1995009611A2 (en) 1995-04-13
KR960700042A (ko) 1996-01-19
HU9502053D0 (en) 1995-10-30
WO1995009611A3 (en) 1995-06-22
DE69431236D1 (de) 2002-10-02
AU7923994A (en) 1995-05-01
AU683698B2 (en) 1997-11-20
ZA947782B (en) 1995-05-17
FI952738A0 (fi) 1995-06-05
NO314064B1 (no) 2003-01-27
DE69431236T2 (de) 2003-01-02
CA2150939C (en) 2001-05-01
JPH08505403A (ja) 1996-06-11
IL111170A (en) 1999-11-30
EP0671905A1 (en) 1995-09-20
HK1010341A1 (en) 1999-06-17

Similar Documents

Publication Publication Date Title
IL117690A0 (en) Stable protein: phospholipid compositions and methods
ES2042693T5 (es) Formulaciones de proteinas plasmaticas y recombinantes en medios de baja potencia ionica.
Ibrahim On the novel catalytically‐independent antimicrobial function of hen egg‐white lysozyme: A conformation‐dependent activity
AU1162099A (en) Prolamin-plant polar lipid combination, preparation method and applications
IT1203515B (it) Complessi di saponine con fosfolipidi e composizioni farmaceutiche e cosmetiche che li contengono
ES2159358T3 (es) Procedimiento para elaborar preparaciones de liposomas.
EA199900715A1 (ru) Липидные комплексы и липосомы совершенно нерастворимых комплексов платины
EE9700249A (et) Liitlipiidide kasutamine stabiliseerivate lisanditena seedeensüümide segude ravimpreparaatides
ES2077904T3 (es) Obtencion y uso de preparados estables de liposomas en forma de pequeñas particulas.
PT671905E (pt) Composicoes estaveis de proteinas: fosfolipidos e respectivos metodos
ATE301709T1 (de) Lipidabkömmlinge von pentaerythritol
DK0740547T3 (da) Liposomer indeholdende deri indkapslede proteiner, fremgangsmåde til deres fremstilling, samt farmaceutiske og kosmetiske p
RU95117866A (ru) Фосфолипидные композиции и способ их получения
EP0515246A3 (fr) Compositions protéiques à textures onctueuse
DE69520231D1 (de) Liposomzubereitungen enthaltend hybrid-interferon
RU94045945A (ru) Способ повышения экспрессии рекомбинантных белков, применение фракции яичного желтка
Bouma STUDIES ON THE INTERACTION BETWEEN SMALL SONICATED PHOSPHATIDYLCHOLINE VESICLES AND HUMAN ERYTHROCYTES.